Kos’ Niaspan/Simvastatin Combination NDA Planned For 2006
This article was originally published in The Pink Sheet Daily
Executive Summary
Two pivotal trials for the extended-release niacin/simvastatin fixed-dose combination are underway, Kos says. Firm expects the new combo to be superior to predecessor Advicor in lowering LDL-cholesterol and similar in raising HDL-C.
You may also be interested in...
Kos Inhaled Insulin Comparable To Lantus In Phase IIa Trial, Firm Says
Kos' inhaled insulin formulation demonstrated equivalent efficacy and safety compared to Aventis' injectable basal insulin analog Lantus in a Phase IIa study, the firm reported Aug. 26
Vytorin Labeling Shows Superiority To Lipitor, Zocor
Merck/Schering-Plough Vytorin sales reps will use clinical data in FDA-approved labeling demonstrating superiority in reducing LDL cholesterol to both Merck's Zocor and Pfizer's Lipitor
Merck/Schering's Vytorin Clears FDA
Zetia/Zocor fixed-dose combination will be marketed as a first-line therapy for cholesterol.